🔹 Revenue: $255.7M (Est: $248M) 🟢
🔹 Adj EPS: ($0.24) (Est: -$0.27) 🟢
🔹 Adj EBITDA: ($16.2M) (Est: -$22M) 🟢
FY25 Guidance
🔹 Revenue: $1.25B (Est: $1.24B) 🟢
🔹 Adj EBITDA: +$5M (Est: $5M) 🟡
Other Q1 Metrics:
🔹 Net Loss: ($68.0M) (vs. $64.7M YoY)
🔹 Gross Profit: $155.2M (vs. $77.7M YoY) +99.8%
🔹 Gross Margin: ~61%
Segment Breakdown
🔹 Genomics Revenue: $193.8M (+88.9% YoY)
🔹 Oncology Testing: $119.0M (+31% YoY)
🔹 Hereditary Testing (Ambry): $63.5M (+23% unit growth)
🔹 Data & Services Revenue: $61.9M (+43.2% YoY)
🔹 Insights/Data Licensing Growth: +58% YoY
Strategic & Operational Highlights
🔸 Secured $200M in model/data licensing deals via AstraZeneca & Pathos collaboration
🔸 Completed Ambry Genetics acquisition
🔸 Announced new partnerships with Illumina & Deep 6 AI
🔸 Launched olivia, an AI-powered personal health concierge
🔸 National rollout of xT CDx test at $4,500 per test
🔸 Adj EBITDA improved by $27.8M YoY